Innovation
Innovation drives disease prevention
We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.
Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
- Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
- US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features